Results 51 to 60 of about 9,061 (176)
Breast Cancer: Targets and Therapy, 2023 Elisabeth M Jongbloed,1 Hedwig M Blommestein,2 Hannah M van Schoubroeck,2 John WM Martens,1 Saskia M Wilting,1 Carin A Uyl-de Groot,2 Agnes Jager1 1Department of Medical Oncology; Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 2Erasmus School ...
Jongbloed EM +6 more
doaj
Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia
Asia-Pacific Journal of Clinical Oncology, EarlyView.Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski +6 more
wiley +1 more source
BMC CancerObjective This study explored the predictors of abemaciclib discontinuation, a cyclin-dependent kinase 4 and 6 inhibitor, in patients with breast cancer.
Noriaki Kataoka +9 more
doaj +1 more source
Asia-Pacific Journal of Clinical Oncology, EarlyView.Evidence‐informed recommendations emphasize the integration of CDK4/6 inhibitors with endocrine therapy as a central component in the management of HR+/HER2− advanced breast cancer in Indonesia. Expanding access and facilitating integration within national treatment frameworks are crucial to improve outcomes and reduce disparities in care.
Sonar Soni Panigoro +9 more
wiley +1 more source
ANZ Journal of Surgery, EarlyView.ABSTRACT Background Axillary surgery in breast cancer has undergone progressive de‐escalation. The recent Sentinel Node versus Observation after Axillary Ultrasound (SOUND) and Intergroup Sentinel Mamma (INSEMA) trials have demonstrated that sentinel lymph node biopsy may be safely omitted in selected patients. This study aimed to evaluate the clinical
Matea Dominkovic +5 more
wiley +1 more source
PI3K p110α Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells
, 2020 Targeting cell cycle regulation in colorectal cancer has not been fully evaluated. We investigated the efficacy of the CDK4/6 inhibitor, abemaciclib, and confirmed a synergistic interaction for PI3K p110α and CDK dual inhibition in colorectal cancer cell
Milang Nam +11 more
core +1 more source
UK recommendations for Ki‐67 immunohistochemical staining and interpretation in breast cancer
Histopathology, EarlyView.Where possible, a validated digital imaging system should be utilized. If this is not available, then intermediate scores (5%–30%) should be thoroughly assessed using the Ki‐67 International Working Group guidance. Difficult cases should be double scored.
Abeer M Shaaban +9 more
wiley +1 more source
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
, 2020 peer reviewedBACKGROUND: Abemaciclib is a selective cyclin-dependent kinase 4 and 6 inhibitor administered continuously for hormone receptor-positive (HR(+)), human epidermal growth factor receptor 2-negative (HER2(-)) advanced breast cancer. Abemaciclib
Jerusalem, Guy +14 more
core +1 more source
Chinese Medical Journal. Background:. In the interim analysis of MONARCH plus, adding abemaciclib to endocrine therapy (ET) improved progression-free survival (PFS) and objective response rate (ORR) in predominantly Chinese postmenopausal women with HR+/HER2− advanced breast ...
Xichun Hu +16 more
doaj +1 more source
MedComm – Oncology, Volume 5, Issue 4, December 2026.This multicenter real‐world study showed that higher BMI (≥ 25 kg/m2) was independently associated with improved PFS in patients with HR+/HER2− advanced breast cancer receiving CDK4/6 inhibitors. Safety outcomes were comparable between BMI groups, and the findings were consistent across alternative BMI thresholds, suggesting the potential prognostic ...
Min Tian +12 more
wiley +1 more source